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ABSTRACT: This present study investigated the effect of
Captisol, a chemically modified cyclodextrin, on the in vitro
dissolution of glimepiride. We prepared glimepiride−Captisol
complexes of different mass ratios (1:1, 1:2, and 1:3 w/w) by a
physical mixing or freeze-drying technique, and found that
complexation with Captisol enhanced the water solubility of
glimepiride. Molecular docking and dynamic simulation predicted
complex formation; at the same time, Fourier transform infrared spectroscopy, differential scanning calorimetry, powder X-ray
diffractometry, and scanning electron microscope indicated molecular interactions that support complexation. We also found that an
inclusion complex was better than a physical mixture in enhancing the complexation of glimepiride with Captisol and enhancing
water solubility. Phase solubility study of the glimepiride−Captisol complex showed an AL-type profile, implying the formation of a
1:1 inclusion complex. The study also revealed that pH influenced the stability of the complex because the stability constant of the
glimepiride−Captisol complex was higher in distilled water of pH ∼6.0 than in phosphate buffer of pH 7.2.
■ INTRODUCTION
Glimepiride (Figure 1) is a long-acting, second-generation
sulfonylurea drug indicated for type 2 diabetes mellitus.1 The
drug is poorly water-soluble, which limits its bioavailability and,
ultimately, efficacy2,3 and therefore creates a critical need to
enhance the water solubility of the drug. In this regard, there are
intensive efforts to apply solubility enhancement techniques
such as encapsulation within cavitands to improve glimepiride
solubility. Well-known cavitands are cyclodextrins (Figure 1),
which encapsulate poorly water-soluble drugs within their
hydrophobic cavity and, through their hydrophilic exterior,
enhance water solubility.4−9 Ammar’s group, for instance,
designed different drug−cyclodextrin−polymer ternary systems
to enhance the solubility of glimepiride,8−10 and Uekama’s
group integrated cyclodextrin into drug carriers to improve the
solubility of the drug.11 In the ternary system, the cyclodextrin
forms both inclusion and noninclusion complexes with
glimepiride, leading to an increase in the drug’s solubility.8,9
Depending on the concentration of cyclodextrin in the system,
aggregates of 1:1 or 1:2 glimepiride−cyclodextrin inclusion
complexes are assembled, which can further solubilize the drug
via noninclusion complexation or micelle-like structure.7−10
The structure of the cyclodextrin plays a critical role in drug
solubilization. Uekama’s group found that glimepiride forms
more water-soluble complexes with α- and β-cyclodextrins than
with γ-cyclodextrin,11 implying that structural and functional
modifications could fine-tune drug solubilization properties.
Sulfobutylether-β-cyclodextrin (SBE7-β-CD) (Figure 1) typifies
a chemically modified cyclodextrin with improved solubility and
reduced systemic toxicity.12 Recently, Captisol, a chemically
modified β-cyclodextrin (Figure 1), was designed to maximize
safety and enhance drug solubility, stability, and bioavail-
ability.13 Preclinical and clinical evaluations suggest that
Captisol is less toxic than β-cyclodextrin and provides more
interactions to enhance water solubility of poorly water-soluble
drugs.14 These superior properties have triggered an interest in
using Captisol to solubilize and stabilize poorly water-soluble
drugs.15−17 Here, we hypothesize that Captisol complexes
glimepiride within the hydrophobic cavity to enhance the drug’s
solubility in aqueous media.
The goal of this study is to test the hypothesis by formulating a
glimepiride−cyclodextrin solid dispersions, physical mixture
and inclusion complex, and then study the drug’s solubility. The
solid dispersions were prepared using freeze-drying and physical
mixing techniques. We carried out phase solubility studies to
understand how temperature and pH affect the solubility of the
glimepiride−Captisol inclusion complex. We also conducted
molecular docking and simulation experiments to predict
complex formation and stability. Powder X-ray diffractometry
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(PXRD), differential scanning calorimetry (DSC), scanning
electron microscopy (SEM), and Fourier transform infrared
spectroscopy (FTIR) were carried out to confirm Captisol
complexation with glimepiride.
■ RESULTS AND DISCUSSION
Stability of Glimepiride Depends on pH. The objective
of this study is to enhance the water solubility of glimepiride, a
hydrophobic drug indicated for type 2 diabetes mellitus. Our
approach to achieving this objective is to use Captisol, a
modified β-cyclodextrin, which improves the water solubility of
various hydrophobic drugs.13,15−18 Toward this, we first
evaluated the saturation solubility of glimepiride by measuring
the drug concentration in its saturated solution of distilled water,
hydrochloric acid buffer (pH 1.2), or phosphate buffer (pH 7.2)
at 10 or 35 °C. The measured concentration depends more on
pH than on temperature, with higher drug concentration
measured in distilled water than in hydrochloric acid or
phosphate buffer (Table 1). It is plausible to attribute the low
concentration in hydrochloric acid or phosphate buffer to poor
solubility; however, this is unlikely because these pH conditions
should facilitate dissolution. Under these conditions, the amide
group in the drug could become positively or negatively charged
in the acidic hydrochloric acid or slightly alkaline phosphate
buffer,19 respectively, enhancing drug solubilization. A more
likely explanation, however, is that at these conditions, acid or
alkaline hydrolysis of the drug occurs, resulting in drug
degradation and ultimately lowering the concentration. Indeed,
literature precedence suggests that glimepiride degrades under
acidic or alkaline conditions, lowering drug concentration.20
Given the likely degradation of the drug at acidic pH, we decided
to evaluate the thermodynamic parameters for glimepiride−
Captisol interactions and phase solubility studies only in distilled
water (pH 6) and phosphate buffer (pH 7.2). On the other hand,
we attributed the negligible effect of temperature on the
saturation solubility of glimepiride (Table 1) to the inherent
complexity in the relationship between hydrophobic effect and
temperature. Indeed, considering that hydrophobic effect exerts
its most substantial effect around 20 °C and then decreases
above and below this temperature,21 we expected the solubility
of glimepiride at 10 and 35 °C to differ slightly.
Captisol EnhancesWater Solubility of Glimepiride.We
prepare glimepiride−Captisol solid dispersion by physically
mixing the powdered form of both compounds to form a
physical mixture or freeze-drying a homogeneous solution of
both compounds to form an inclusion complex. In both
approaches, different glimepiride/Captisol mass ratios (1:1,
1:2, and 1:3 w/w) were obtained by varying the mass of Captisol
in the solid dispersion. The water solubility of glimepiride in the
physical mixture and inclusion complex was compared with that
of the pure drug to obtain a solubility enhancement factor, which
is the ratio of the amount of glimepiride that dissolves from the
physical mixture or inclusion complex into distilled water to that
from the pure drug. In distilled water, the enhancement factor
increases, indicating that Captisol enhances the water solubility
of glimepiride. Also, glimepiride solubility increases with mass
ratio because a 1:3 ratio yielded over 1-fold increase in
enhancement factor (Figure 2). For instance, in the inclusion
complex, no significant increase was observed at a 1:1 ratio, but
∼2-fold and ∼3-fold increases in enhancement factor were
found at ratios of 1:2 and 1:3, respectively (Figure 2). We found
that increasing the amount of Captisol in the physical mixture or
inclusion complex increases the drug solubility in distilled water
(Table 2) and that the enhancement factor of inclusion
complexes was better than that of physical mixtures. Our
finding concurs with a previous report that shows the superiority
of the Captisol inclusion complex over a physical mixture in
enhancing water solubility of hydrophobic drugs such as
Figure 1. (a) Chemical structure of glimepiride. (b) Chemical structure
of some cyclodextrins.
Table 1. Saturation Solubility of Glimepiride in Different
Media and Various Temperatures
solubility of
glimepiride (μg/mL)
solutions 10 °C 35 °C
distilled water 0.53 0.56
phosphate buffer (pH 7.2) 0.49 0.49
hydrogen chloride acid buffer (pH 1.2) 0.26 0.27
Figure 2. Solubility enhancement factors of glimepiride in physical
mixtures and inclusion complexes in distilled water.
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ibuprofen.15 Also, our observation that the dissolution of
glimepiride increases with the concentration of the cyclodextrin
agreed with a previous report.10
Phase Solubility Profiles Indicate an AL-Type Glime-
piride−Captisol Inclusion Complex and a Strong
Interaction between both Compounds. Intrigued by the
ability of Captisol to enhance the water solubility of glimepiride,
we investigated the binding constants between the two
compounds using phase solubility profiles in distilled water
and phosphate buffer (pH 7.2) at 10 and 35 °C. The solubility
profiles were obtained by plotting the molar concentration of
glimepiride against that of Captisol. According to Higuchi’s
phase solubility profile classification,22 a solubility phase is an
AL-type if the drug solubility increases linearly with the
concentration of Captisol in the solvent. In this study, the
linearity of the curves and values of the slope, which are less than
one (Figure 3), suggests that the drug exhibited an AL-type
behavior. The increase in drug solubility with Captisol agrees
with previous findings and is consistent with the solubility
enhancement nature of cyclodextrin derivatives.15
Table 3 shows the apparent stability constants and other
thermodynamic parameters for interactions of Captisol with
glimepiride at various temperatures. The stability constant (Kc)
was calculated from the slope and intercept of the phase
solubility diagram (Figure 3), which depends on the molecular
weight and binding capacity of the drug and Captisol. The Kc of
glimepiride in phosphate buffer was 3 and 73 M−1 at 10 and 35
°C, respectively (Table 3). As the value of Kc lies between 50−
2000 M−1 at 35 °C, we inferred that Captisol interacts with the
drug to improve the physical and chemical characteristics of the
latter.23 We found the change in Gibbs free energy (ΔG) to be
negative for all the samples, implying that complexation between
Captisol and glimepiride was spontaneous, which concur with
previously reported interactions between β-cyclodextrin and
ibuprofen15 or ketoprofen.24
We also evaluated Kc of glimepiride in distilled water and
obtained values of 29 and 83 M−1 at 10 and 35 °C, respectively.
At 35 °C, these values lie between the 50−2000 M−1 range,
indicating that the interactions in Captisol are sufficient to
solubilize the drug. Again, the negative ΔG values confirm the
spontaneity of the binding interaction between Captisol and
glimepiride, while the positive values of the change in enthalpy
(ΔH) indicate that the interaction was endothermic. The
positive values of entropy change (ΔS) (Table 3) imply
increased disorderliness, presumably due to enhanced dis-
Table 2. Concentration (Solubility) of Glimepiride
Solubilized into Distilled Water from the Physical Mixture
and Inclusion Complex




Figure 3. Phase solubility profile of glimepiride in (a, b) phosphate buffer pH 7.2 and (c, d) distilled water pH 6.0 at (a, c) 10 °C and (b, d) 35 °C.
Table 3. Thermodynamic Parameters of Glimepiride and
Captisol Complex System
distilled water, pH 6.0 phosphate buffer, pH 7.2
parameter 10 °C 35 °C 10 °C 35 °C
intercept (M) 0.0006 0.001 0.001 0.001
slope 0.02 0.08 0.008 0.08
Kc (M
−1) 29 83 8 73
CE 0.02 0.08 0.008 0.09
ΔG (kJ/mol) −8 −11 −5 −11
ΔH (kJ/mol) 31 63
ΔS (J/mol/K) 134 240
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solution of the glimepiride in Captisol, and also support the
spontaneity of the drug−Captisol interaction, as evidenced by
the negative ΔG values.25
A previous study of inclusion complexes of various cyclo-
dextrins with the hydrophobic drug, naproxen, showed that
under acidic conditions, the unionized form of the drug forms a
more stable complex with the negatively charged cyclodextrin
compared with the ionized form.26 In this study, we assumed
that the negatively charged Captisol formed a more stable
complex with unionized or partially positively charged
glimepiride in distilled water (∼pH 6) than its negatively
charged form in phosphate buffer (pH 7.2). Indeed, at pH 7.2, a
negatively charged glimepiride electrostatically repels the
negatively charged Captisol, whereas at pH 6, a slightly
positively charged drug electrostatically attracts and complexes
the negatively charge Captisol.
Molecular Docking and Molecular Dynamics Simu-
lation Support Formation of Inclusion Complex. We
conducted molecular docking of pure glimepiride with β-
cyclodextrin using MOE 2019.01 to understand the binding
affinity and stability of the inclusion complex. We used β-
cyclodextrin for the docking experiment because Captisol is a
modified β-cyclodextrin but most importantly is a proprietary
compound with undisclosed structure. The energy minimized
structure obtained from the docking experiment predicts that β-
cyclodextrin can encapsulate glimepiride within its hydrophobic
cavity (Figure 4). The experiment also predicts the formation of
the β-cyclodextrin−glimepiride inclusion complex with a
binding energy of −120 kJ/mol. Previous reports assert that
negative binding energy indicates a stable inclusion com-
plex.15,27 Using GROMACS, we also performed molecular
dynamic simulations to substantiate the docking experiment and
to calculate the binding free energy of the docked complexes.
Three energetic terms for calculation of changes in binding free
energy were done through the MM_PBSA method, which was
calculated using the g_mmpbsa tool.28 The experiments, which
were run for 100 ns, fetch information from the GROMACS
trajectory file and calculate the total free energy for β-
cyclodextrin−glimepiride docked complexes. We also calculated
the van der Waals energy, electrostatic energy, polar solvation
energy, SASA energy, and overall binding energies (Table 4).
Solid-State Analyses Show that Glimepiride Interacts
with Captisol. To substantiate the results of the computer
simulation that indicate that Captisol interacts with glimepiride,
we used SEM, FTIR, PXRD, and DSC for solid-state analyses of
the physical mixture and freeze-dried inclusion complex. SEM
images revealed solid-state glimepiride and Captisol as flake-
shaped and spherical materials, respectively (Figure 5). The
morphologies of the inclusion complex and the physical mixture
differ considerably due to differences in processing procedures
(Figure 5). For instance, we observed drug residues on the
surface of the physical mixture, which contrasts with the
inclusion complex, where none was present on the surface
(Figure 5), probably as a result of encapsulation with the
hydrophobic core. The FTIR spectra of glimepiride andCaptisol
showed the expected absorption bands and a shift in bands of the
physical mixture, probably because of the interaction between
the two compounds (Figure 6). For the inclusion complex, some
characteristic bands of Captisol and glimepiride were absent; for
example, the band at 3284 cm−1 (NH stretching) associated
with glimepiride was not observed (Figure 6). Previously, FTIR
confirms the formation of an inclusion complex,29 and we infer
from the results of this study that the observed changes in the
FTIR spectrum of glimepiride and Captisol in the inclusion
complex support the formation of drug complexation.
The PXRD diffractogram of the glimepiride was sharp and
intense, confirming the expected crystallinity of the drug, while
that of Captisol was broad, indicating amorphousness (Figure
7). The diffractogram of the physical mixture (mass ratio of 1:3)
showed peaks that were characteristic of glimepiride, although
many peaks shifted while some were absent. The diffractogram
of inclusion complexes (mass ratio of 1:1) was broad, and the
characteristic crystalline peaks of glimepiride were absent,
presumably due to the encapsulation of glimepiride within the
hydrophobic cavity of Captisol. A previous report shows that
drugs encapsulated with cyclodextrin lose their crystallinity; for
instance, pimozide was found to lose its crystallinity in a β-
cyclodextrin-poly(vinylpyrrolidone) inclusion complex, result-
ing in an enhanced water solubility.30 We also performed DSC
analyses to probe the interactions between glimepiride and
Captisol. The thermogram (Figure 8) of glimepiride shows an
endotherm at 211 °C and enthalpy of fusion (ΔHf) of 88 J/g
while that of Captisol showed an endotherm at 265 °C. The
thermogram of the physical mixture exhibited the typical
endotherms of glimepiride and Captisol. We attributed the
endotherm at ∼210 °C to complexation between the drug and
Captisol. In the thermograms of the inclusion complexes, the
glimepiride endotherm disappeared, suggesting that the drug
was encapsulated in the cavity of Captisol.
Figure 4. β-cyclodextrin−glimepiride docked inclusion complex. Blue
molecule denotes glimepiride, and orange molecule denotes β-
cyclodextrin.
Table 4. Binding Free-Energy Calculation of the β-
Cyclodextrin−Glimepiride Inclusion Complex with
Individual Component Contributing to Total Binding Free
Energy in MM_PBSA Method
parameters values
van der Waals energy (kJ/mol) −127.21 ± 5.78
electrostatic energy (kJ/mol) −4.92 ± 0.55
polar solvation energy (kJ/mol) 24.88 ± 1.25
SASA energy (kJ/mol) −12.14 ± 0.44
binding energy (kJ/mol) −119.52 ± 5.49
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In Vitro Dissolution Study Shows that Captisol
Enhances Water Solubility of Glimepiride. We evaluated
the in vitro dissolution of glimepiride from the pure powdered
form, physical mixture, and inclusion complex at physiological
pH (7.2) and temperature (37 °C) conditions. We found that
the drug in physical mixtures dissolved faster than in the pure
form, with almost 44% of glimepiride being solubilized within 90
min (Figure 9). The drug in the inclusion complex had the
fastest dissolution rate, with 100% of the drug being solubilized
within 90 min. We attribute the enhanced water solubility of the
drug in the physical mixture and inclusion complex to Captisol,
which enhances the wettability of glimepiride through the
formation of a hydrodynamic film around the drug particles, or
solubilization of Captisol within the microenvironment, as
demonstrated with acyclovir−hydroxypropyl-β-cyclodextrin
complex.31 Previous studies have shown that water solubility
of drugs is higher in inclusion complexes than in physical
mixtures or pure drugs.30 We attributed the slow dissolution of
glimepiride from the inclusion complexes within the first 20 min
to the fractional entrapment of glimepiride molecules inside the
cyclodextrin cavity.
In conclusion, we prepared glimepiride−Captisol solid
dispersions by a freeze-drying or physical mixing technique to
increase the water solubility of the hydrophobic type 2 diabetes
drug, glimepiride. Captisol is a modified β-cyclodextrin with a
hydrophobic cavity that can encapsulate and solubilize
glimepiride and a hydrophilic exterior that ensures that the
encapsulated drug is homogeneously dispersed in an aqueous
medium. Our molecular docking experiment predicts that β-
cyclodextrin encapsulates and stabilizes glimepiride. Empirical
data from PXRD, DSC, SEM, and FTIR confirm that Captisol
interacts with glimepiride. Indeed, PXRD indicates that Captisol
encapsulates glimepiride because the characteristic crystalline
peaks of the drug disappear upon the formation of the inclusion
complex. These interactions and encapsulation phenomenon
enhance the water solubility of the drug. Indeed, in vitro
dissolution experiments show that the water solubility of
glimepiride in the physical mixture and inclusion complex was
higher than that in the pure drug. Overall, our results show that
Captisol can enhance the water solubility of hydrophobic drugs
to improve their bioavailability.
■ MATERIALS AND METHODS
Materials.Glimepiride and Captisol were a gift from Indoco
Remedies Ltd., Baddi, Katha, Himachal Pradesh, India, and
CyDex Pharmaceuticals Inc., Kansas, USA, respectively. Other
reagents and solvents were of analytical grade and used without
any further purification.
Determination of Saturation Solubility of Glimepiride.
To determine the saturation solubility of glimepiride, we added
an excess amount of glimepiride to 20 mL of an appropriate
medium (pH 7.2 phosphate buffer, pH 1.2 hydrochloric buffer,
or distilled water) maintained at 10 °C or 35 °C and stirred
continuously with a magnetic stirrer.15 After equilibrium, the
sample was centrifuged, and the supernatant was recovered by
filtration. The filtrates were diluted, and their absorbances were
monitored using a UV spectrophotometer at a wavelength of
228 nm while the drug concentration was obtained from a
standard curve.
Preparation of Physical Mixtures of Glimepiride with
Captisol. Different mass ratios (1:1, 1:2, and 1:3 w/w) of
glimepiride and Captisol were mixed and homogenized by
triturating using a mortar and pestle for 30 min.32 The mass of
Captisol was varied while that of glimepiride was kept constant.
Preparation of Inclusion Complexes of Glimepiride
and Captisol Using Freeze-Drying.The inclusion complexes
were prepared by dissolving the glimepiride and Captisol at
different mass ratios (1:1, 1:2, and 1:3) in water to form a
homogeneous mixture. Briefly, the weighted glimepiride was
added to water and stirred, and then the weighted Captisol was
Figure 5. Scanning electron micrographs: (a) pure glimepiride, (b) Captisol, (c) glimepiride−Captisol physical mixture, (d) glimepirideCaptisol®
inclusion complex.
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added to the solution and stirred for 24 h using a magnetic
stirrer. The solution was filtered, and the filtrate was freeze-dried
at −40 °C under vacuum for 12 h until a dried powder was
obtained.33
Drug Content Determination. The drug contents in the
physical mixtures and inclusion complexes were determined
according to the previously described method.34 Briefly, 10 mg
of physical mixture or inclusion complex was added into 10 mL
of DMF/water solvent (1:1, v/v) to dissolve both the free and
complexed glimepiride. Then, the solutions were stirred,
centrifuged for 10 min at 4000 rpm, filtered, and then diluted,
and the drug content was quantified at 228 nm using a UV
spectrophotometer (UV Shimadzu 1800, India).
Phase Solubility Study. The experiment was carried out at
10 or 35 °C in pH 7.2 phosphate buffer or distilled water18 and
with different molar concentrations of glimepiride and Captisol.
A phase solubility diagram was constructed using the molar
concentration of glimepiride against that of Captisol.22 Using
the following equation,12,15,26,35 the apparent stability (binding)
constants (Kc) of different glimepiride−Captisol complexes
were calculated by:
Figure 6. FTIR spectra of (a) glimepiride, (b) Captisol, (c) glimepiride−Captisol 1:1 physical mixture, (d) glimepiride−Captisol 1:1 inclusion
complex, (e) glimepiride−Captisol 1:2 physical mixture, (f) glimepiride−Captisol 1:2 inclusion complex, (g) glimepiride−Captisol 1:3 physical
mixture, and (h) glimepiride−Captisol 1:3 inclusion complex.
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where S0 (intrinsic solubility) is the intercept of the phase
solubility curve and denotes the saturation solubility of
glimepiride in distilled water or phosphate buffer without
Captisol at different temperatures and the “slope” denotes the
slope of the straight line.
The complexation efficiency (CE) was calculated from the
phase solubility diagram:12,15,26,35
S KCE 0 c= (2)
Change in enthalpy (ΔH) of complexation was calculated















where K2 and K1 are the stability constants at T2, and T1
temperatures, respectively, and the temperatures were in Kelvin.
The changes in Gibbs free energy (ΔG) and entropy (ΔS)
due to complexation were determined from the following
equations:12,15,26,35
Figure 7. Powder X-ray diffractogram of (a) pure glimepiride, (b) Captisol, (c) glimepiride−Captisol 1:1 physical mixture, (d) glimepiride−Captisol
1:3 physical mixture, (e) glimepiride−Captisol 1:1 inclusion complex, and (f) glimepiride−Captisol 1:3 inclusion complex.
Figure 8. DSC curves of glimepiride, Captisol, physical mixtures, and glimepiride−Captisol inclusion complexes.
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( )Δ = Δ − Δ
(5)
where R is the gas constant (R = 8.314 J/mol/K), and K is
apparent stability constant from eq 1.
Molecular Docking Studies of Glimepiride−β-Cyclo-
dextrin Complexes.Themolecular docking experiments were
carried out using the Chemical Computing Group’s Molecular
Operating Environment (MOE) software (MOE 2019.01). The
3D chemical structure of the glimepiride was downloaded from
the PubChem database portal. Both glimepiride and β-
cyclodextrin underwent energy minimization until an RMSD
gradient of 0.05 kcal mol−1 Å−1 was obtained. Amber10: EHT
force field was employed to calculate the partial charges. We
used Triangle matcher as the ligand placement method and
London Dg scoring as Rescoring for docking studies. The
GBVI/WSA dG scoring function was used throughout. In all, 30
poses were generated for each run, and 5 poses were generated
for the refinement stage. The results obtained were under the
following criteria. S score is the final score, RMSD defines the
pose from the original ligand, RMSD refine defines the pose after
the refinement stage, E_conf is the energy of the conformer, and
E_place is the score from the placement stage. The docked pose
with lower energy was recorded in the form of S_Score.
The top-scored complex docking poses were subjected to
solvent-explicit, all-atom molecular dynamics simulations using
the GPU-accelerated Desmond 3.0 (D.E Shaw Research and
Schrödinger Inc.). Models of protein−ligand complexes were
produced using the OPLS3e force field. Each full-atom system
was immersed in a periodic simple point charge (SPC) water
model. Electroneutrality was ensured by adding one Na+ ion to
the system. Periodic boundary conditions and the particle mesh
Ewald method (to account for long-range electrostatic
interactions) were used throughout. Bonds involving hydrogens
were constrained using the SHAKE algorithm, and a time step
integration of 2 fs was used for all simulations. A steepest descent
minimization and thermalization scheme was applied to the
initial structure. The systems were heated from 0 to 300 K in 100
ps, keeping the Cα atoms fixed in their original positions. In the
next step, all the constraints were lifted, and the equilibration
was continued in the isobaric−isothermal ensemble with Nose−
Hoover thermostats for 5.0 ns.
The molecular dynamics simulation of β-cyclodextrin−
glimepiride docked complexes was performed once using the
GROMACS 4.5.52 package, with a standard GROMOS96 force
field for 100 ns.36,37 The simulation was performed in the
presence of water, and an SPC water model was used with 1495
water molecules being added to the complex. After solvating the
system, we neutralized the system with the following Gromacs
command: “genion -s ions.tpr -o solv_ions.gro -p topol.top
-pname NA -nname CL -neutral. The output of the command
and topol.top file suggested that the zero counter ion was added
to the system, as previously reported.38 Each molecular dynamic
production run was carried out for 100 ns for each complex.
Each recording interval was set to 100 ps for the trajectory and
1.2 ps for the energy. The NPT ensemble class with a
temperature of 300 K and a pressure of 1.01325 bar was used.
Each reported value was calculated as the mean of three
molecular dynamics performed for each complex. All other
options were kept on by default values.
Scanning Electron Microscopy. The surface morpholo-
gies of the pure glimepiride, physical mixture, and inclusion
complex were analyzed using a scanning electron microscope
(TM3030 Plus). The powdered samples were mounted on an
aluminum stub using double-sided adhesive carbon tapes and
then coated with platinum under low pressure to make them
electrically conductive. The images of the samples were taken at
an excitation voltage of 10 kV.39
Fourier Transform Infrared Spectroscopy. The analysis
was performed on a Fourier transform infrared spectropho-
tometer (Bruker) to determine functional groups of glimepiride,
Captisol, physical mixture, and inclusion complexes. The
powdered sample was mixed with the KBr powder of infrared
grade at 1% and pressed into a disc using a hydraulic press.
Powder X-rayDiffractionAnalysis.The powdered sample
was analyzed using (XPERT-3) with a CuKα radiation source of
an accelerating voltage of 40 kV and a current of 30 mA (λ =
1.5406 Á̆). The experiment was carried out at room temperature.
The scan range was over the 2θ angle range of 3 to 50°, and the
scan step time was 0.5 s.
Differential Scanning Calorimetry. The analysis was
done by heating 3 mg of each sample from 25 to 300 °C at a
heating rate of 10 °C/min under ultrahigh purity nitrogen gas
Figure 9. Dissolution profiles of glimepiride from the physical mixture (PM in orange), inclusion complex (FD in gray), and pure drug (in blue) in
phosphate buffer (pH 7.2) at 37 °C.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c01228
ACS Omega 2020, 5, 19968−19977
19975
flowing at 150 mL/min. The experiment was performed using
DSC thermograms (STARe SW 12.10).
In Vitro Dissolution of Glimepiride from the Pure
Drug, Physical Mixtures, and Inclusion Complexes. The
dissolution was assessed using the USP apparatus II (paddle
method) (in vitro dissolution apparatus, Lab India DS 8000).40
The experiment was performed for the pure drug, physical
mixtures, and inclusion complexes in a dissolution vessel
containing pH 7.2 phosphate buffer at a temperature of 37 °C.
At different time intervals (10, 20, 40, 60, and 90 min), 1 mL of
sample was withdrawn and subsequently replaced with the
freshly prepared dissolution medium to maintain the sink
condition. The withdrawn samples were then filtered using
Whatman filter paper no.1, and the filtrates were diluted with the
dissolution medium and analyzed for drug concentration using a
UV spectrophotometer at 228 nm.33
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